Although certain genetic analyses, such as O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase 1 (IDH1) status [4], [15], [16], [17], are frequently used in clinical practice, large scale gene- and microRNA based cancer characterization is commonly not performed due to high cost, time and manpower required for data analysis and interpretation [18]. The gene discussed is MGMT; the disease is cancer.